Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irpagratinib + toripalimab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Abbisko Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ABSK-011 + toripalimab + bevacizumab is an investigational triplet combination regimen being developed by Abbisko Therapeutics for the first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC), specifically in patients with FGF19 overexpression. The regimen consists of irpagratinib (ABSK-011), a highly selective oral small-molecule inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4); toripalimab, a humanized monoclonal antibody targeting the Programmed Cell Death Protein 1 (PD-1) receptor; and bevacizumab, a monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF). By targeting three distinct pathways—FGFR4 signaling, immune evasion, and angiogenesis—the combination seeks to provide a synergistic therapeutic effect in HCC patients whose tumors are driven by FGF19/FGFR4 alterations.
- Other names
- ABSK-011 + JS001 + bevacizumab
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on irpagratinib + toripalimab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irpagratinib + toripalimab + bevacizumab.